Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
241-255 of 355
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Peter Schmid, FRCP, MD, PhD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
- advertisement
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Aparna R. Parikh, MD
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
William J. Gradishar, MD
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
- advertisement
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Alan Venook, MD
Erica L. Mayer, MD, MPH
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
